Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

  • Casarrubios, Marta|||0000-0002-2872-9552
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
  • Nadal, Ernest|||0000-0002-9674-5554
  • Insa, Amelia|||0000-0002-3438-6170
  • García Campelo, María del Rosario
  • Lázaro, Martín|||0000-0002-0657-4713
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López-Vivanco, Guillermo|||0000-0003-3800-6224
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Viteri, Santiago|||0000-0002-7572-1123
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Barquín, Miguel
  • Laza-Briviesca, Raquel
  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Parra, Edwin R.|||0000-0001-9068-1636
  • Sanchez-Espiridion, Beatriz
  • Rocha, Pedro
  • Kadara, Humam
  • Wistuba, Ignacio I.
  • Romero, Atocha|||0000-0002-1634-7397
  • Calvo, Virginia|||0000-0002-3503-4847
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non-small cell lung cancer (NSCLC). Experimental Design: In this study, next-generation TCR sequencing was performed in peripheral blood and tissue samples of 40 patients with NSCLC, before and after neoadjuvant chemoimmunotherapy (NADIM clinical trial, NCT03081689), considering their complete pathologic response (CPR) or non-CPR. Beyond TCR metrics, tissue clones were ranked by their frequency and spatiotemporal evolution of top 1% clones was determined. Results: We have found a positive association between an uneven TCR repertoire in tissue samples at diagnosis and CPR at surgery. Moreover, TCR most frequently ranked clones (top 1%) present in diagnostic biopsies occupied greater frequency in the total clonal space of CPR patients, achieving an AUC ROC to identify CPR patients of 0.967 (95% confidence interval, 0.897-1.000; P ¼ 0.001), and improving the results of PD-L1 tumor proportion score (TPS; AUC = 0.767; P = 0.026) or tumor mutational burden (TMB; AUC = 0.550; P = 0.687). Furthermore, tumors with high pretreatment top 1% clonal space showed similar immune cell populations but a higher immune reactive gene expression profile. Finally, the selective expansion of pretreatment tissue top 1% clones in peripheral blood of CPR patients suggests also a peripheral immunosurveillance, which could explain the high survival rate of these patients. Conclusions: We have identified two parameters derived from TCR repertoire analysis that could outperform PD-L1 TPS and TMB as predictive biomarkers of CPR after neoadjuvant chemoimmunotherapy, and unraveled possible mechanisms of CPR involving enhanced tumor immunogenicity and peripheral immunosurveillance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
  • Nadal, Ernest|||0000-0002-9674-5554
  • Garitaonaindiá, Yago
  • Insa, Amelia|||0000-0002-3438-6170
  • Mosquera, Joaquín
  • Casal-Rubio, Joaquín
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López Vivanco, Guillermo
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Viteri, Santiago|||0000-0002-7572-1123
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Laza-Briviesca, Raquel
  • Casarrubios, Marta|||0000-0002-2872-9552
  • Garciá-Grande, Aránzazu
  • Romero, Atocha|||0000-0002-1634-7397
  • Franco, Fernando|||0000-0001-8964-5136
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to chemoimmunotherapy. Methods In order to identify parameters associated to treatment related Pn, we analyzed clinical variables and molecular parameters from 46 patients with potentially resectable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapy included in the NADIM clinical trial (NCT03081689). Pn was defined as clinical or radiographic evidence of lung inflammation without alternative diagnoses, from treatment initiation to 180 days. Results Among 46 patients, 12 developed Pn (26.1%). Sex, age, smoking status, packs-year, histological subtype, clinical or pathological response, progression-free survival, overall survival and number of nivolumab cycles, were not associated to Pn development. Regarding molecular parameters at diagnosis, Pn development was not associated to programmed death ligand 1, TPS, T cell receptor repertoire parameters, or tumor mutational burden. However, patients who developed Pn had statistically significant lower blood median levels of platelet to monocyte ratio (p=0.012) and teratocarcinoma-derived growth factor 1 (p=0.013; area under the curve (AUC) 0.801), but higher median percentages of natural killers (NKs) (p=0.019; AUC 0.786), monocytes (p=0.017; AUC 0.791), MSP (p=0.006; AUC 0.838), PARN (p=0.017; AUC 0.790), and E-Cadherin (p=0.022; AUC 0.788). In addition, the immune scenario of Pn after neoadjuvant treatment involves: high levels of neutrophils and NK cells, but low levels of B and T cells in peripheral blood; increased clonality of intratumoral T cells; and elevated plasma levels of several growth factors (EGF, HGF, VEGF, ANG-1, PDGF, NGF, and NT4) and inflammatory cytokines (MIF, CCL16, neutrophil gelatinase-associated lipocalin, BMP-4, and u-PAR). Conclusions Although statistically underpowered, our results shed light on the possible mechanisms behind Pn development, involving innate and adaptative immunity, and open the possibility to predict patients at high risk. If confirmed, this may allow the personalization of both, the surveillance strategy and the therapeutic approaches to manage Pn in patients receiving chemoimmunotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

  • Casarrubios, Marta|||0000-0002-2872-9552
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Nadal, Ernest|||0000-0002-9674-5554
  • Insa, Amelia|||0000-0002-3438-6170
  • Del Rosario García-Campelo, María|||0000-0003-2113-1504
  • Lázaro, Martín|||0000-0002-0657-4713
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López-Vivanco, Guillermo|||0000-0003-3800-6224
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Martinez-Toledo, Cristina|||0000-0002-0663-0674
  • Fernández-Miranda, Ismael|||0000-0002-5136-7270
  • Serna-Blanco, Roberto|||0000-0002-7563-9613
  • Romero, Atocha|||0000-0002-1634-7397
  • Calvo, Virginia|||0000-0002-3503-4847
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. Unfortunately, a considerable percentage of tumors do not completely respond to therapy, which has been associated with early disease progression. So far, it is impossible to predict these events due to lack of knowledge. In this study, we characterized the gene expression profile of tumor samples to identify new biomarkers and mechanisms behind tumor responses to neoadjuvant chemoimmunotherapy and disease recurrence after surgery. Methods Tumor bulk RNA sequencing was performed in 16 pretreatment and 36 post-treatment tissue samples from 41 patients with resectable stage IIIA NSCLC treated with neoadjuvant chemoimmunotherapy from NADIM trial. A panel targeting 395 genes related to immunological processes was used. Tumors were classified as complete pathological response (CPR) and non-CPR, based on the total absence of viable tumor cells in tumor bed and lymph nodes tested at surgery. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment analysis. CIBERSORTx was used to estimate the proportions of immune cell subtypes. Results CPR tumors had a stronger pre-established immune infiltrate at baseline than non-CPR, characterized by higher levels of IFNG, GZMB, NKG7, and M1 macrophages, all with a significant area under the receiver operating characteristic curve (ROC).